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Abstract
Introduction. PLAGL1 (pleiomorphic adenoma gene-like 1) is a C2H2-type zinc finger transcription factor as-
sociated with the regulation of cell growth and development. Although PLAGL1 expression in kidney was 
assessed by biochemical methods, the exact localization of the PLAGL1 protein in human kidney has not yet 
been described. 
Material and methods. Macroscopically unchanged specimens of kidney tissue were collected from 39 patients 
undergoing nephrectomy due to renal cell carcinoma. H & E staining of paraffin sections was used to assess his-
tology of the kidney whereas immunohistochemistry was used to localize PLAGL1 protein in kidney compart-
ments. In addition, database sequences search for putative PLAGL1 binding sites among the kidney-related 
genes was performed. 
Results. PLAGL1 staining intensity differed depending on the kidney compartment. Strong PLAGL1 immu-
noreactivity was found in thick ascending limbs of Henle’s loop, distal tubules and collecting ducts, whereas 
PLAGL1 expression in proximal tubules and renal corpuscles (including podocytes) was moderate and weak, 
respectively. By the in sillico screening of promoter sequences for PLAGL1 specific DNA-binding sites GGG-
GCCCC we designated 43 candidate genes for PLAGL1-regulated genes. Analysis of their functional annota-
tions identified three significantly over-represented gene sets: inositol phosphate metabolic processes (GO), 
endocrine and other factor-regulated calcium reabsorption (KEGG) and calcium signaling pathways (KEGG). 
Conclusion. Differences in the renal expression of PLAGL1 suggest that this protein may be involved in the 
regulation of several cellular pathways both as transcriptional factor and coactivator/corepressor of other tran-
scription factors reflecting its role in the cell type-specific control of gene expression. (Folia Histochemica 
et Cytobiologica 2015, Vol. 53, No. 1, 96–104)
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PLAGL1 is a C2H2-type zinc finger transcription 
factor, encoded by the PLAGL1 gene (pleiomorphic 
adenoma gene-like 1; known also as ZAC1 for Zinc
-finger protein which regulates apoptosis and cell-cycle 
arrest or LOT1 for Lost-on-transformation 1). Many 
transcript variants encoding two main PLAGL1 iso-
forms (44.7 and 50.8 kDa) were found for this gene 
(Ensembl ENSG00000118495). PLAGL1 is ubiquito-
usly expressed in a number of normal embryonic and 
adult tissues [1, 2]. Studies performed so far allowed 
to determine PLAGL1 as a factor contributing to the 
regulation of cell growth and differentiation in seve-
ral physiological and pathological processes. It was 
shown that PLAGL1–/– knock-out mice demonstrated 
fetal growth retardation, altered bone formation and 
neonatal mortality [3]. In the course of the embryonic 
development an increased PLAGL1 expression was 
detected in the nervous system, chondrogenic tissue, 
liver, myocardium and skeletal system [2]. The studies 
on the transient neonatal diabetes mellitus (TNDM) 
indicate the role of the PLAGL1 gene overexpression 
in etiopathogenesis of this disease [4, 5]. PLAGL1 was 
proposed as a putative tumor suppressor gene as it 
shares its anti-proliferative and pro-apoptotic activity 
with TP53, i.e. inhibits cell growth and promotes cell 
cycle arrest [6, 7]. PLAGL1 gene deletion as well as 
decrease of its expression were found in many types 
of human neoplasms: breast and ovarian cancers, ba-
socellular skin cancer and adrenal gland tumors [1, 2]. 
Previous studies reported that PLAGL1 binds 
DNA and can act as a transcription factor by sequ-
ence-specific DNA binding [1, 8]. The consensus 
binding nucleotide sequence for PLAGL1 was iden-
tified as GGGGGGCCCC [1]. It was documented 
that PLAGL1 can improve DNA-binding activity of 
histone acetyltransferases, stabilize p53 and enhance 
p53-dependent gene expression [9–12]. PLAGL1 can 
also act as transcriptional coactivator or corepressor 
of hormone-dependent activity of nuclear recept- 
ors [12]. The latter can be supported by the fact that 
in adults PLAGL1 mRNA shows a high expression 
in most steroid-responsive tissues, including human 
kidney [1]. 
The aim of our study was to provide information 
about the localization of the PLAGL1 protein in 
normal human kidney using immunohistochemical 
(IHC) technique. We found much stronger PLAGL1 
immunoreactivity in thick ascending limbs of Henle’s 
loop, distal tubules and collecting ducts than in proxi-
mal tubules and podocytes. We sought to combine our 
experimental and in sillico data to suggest possible 
role of PLAGL1 in the functions of human kidney.
Material and methods
Patients. This study was approved by the Bioethical Com-
mission of the University of Warmia and Mazury (per-
missions No. 4/2010 and 33/2010). A written agreement 
was obtained from each participant. Postoperative kidney 
samples were harvested from patients subjected to radical 
nephrectomy due to renal cell carcinoma who were op-
erated on in the years 2010–2012 in Warmia and Mazury 
Oncological Center in Olsztyn, Poland. Specimens were 
obtained from 39 patients: 23 males and 16 females, aged 
between 31 and 83 years (62.7 ± 10.5 years; mean ± SD). 
Directly after the nephrectomy, specimens for routine his-
tological evaluation and IHC staining were resected from 
macroscopically cancer-free part of the kidney and fixed in 
4% buffered-formaldehyde (pH 7.4). Simultaneously, kidney 
tissue samples for Western blot analysis were frozen in liquid 
nitrogen and stored at –80°C.
Validation of anti-human PLAGL1 antibodies by Western 
immunoblotting. Prior to the IHC, the utility of primary 
antibody for staining procedure was validated using Western 
blotting technique. Homogenates were prepared from six 
macroscopically unchanged parts of kidneys and immuno-
blotting procedure using the rabbit monoclonal anti-human 
PLAGL1 antibody (1:1000; Anti-PLAGL1/ZAC antibody, 
#ab129063, Abcam, Cambridge, UK) was performed 
according to the previously described procedure [13]. Ho-
mogenate of human tonsil was used as immunoblotting the 
positive control. Spectra Multicolor High Range Protein 
Ladder (Thermo Fisher Scientific, #26625; Waltham, MA, 
USA) was used as a molecular mass marker.
Tissue sampling and immunohistochemistry. Kidney tissue 
specimens of 39 patients were processed in ethanol and 
xylene and embedded in paraffin. Seven μm thick tissue 
sections were cut, mounted on gelatin-coated slides, de-
paraffinized and rehydrated. Antigen retrieval was carried 
out using Epitope Retrieval Solution (Dako, Glostrup, 
Denmark) and microwaving (ca 100°C, 4 times for 5 min), 
cooled, and washed for 30 min in PBS, pH 7.4. Endogenous 
peroxidase activity was quenched by the incubation of 
sections in 3% hydrogen peroxide solution in methanol for 
10 min. Then, the sections were washed in PBS and incu-
bated for 30 min in 2.5% horse serum (Abcam) as a serum 
blocking procedure. Subsequently, primary antibody, rabbit 
monoclonal anti-human PLAGL1 (1:2000; Anti-PLAGL1/ 
/ZAC antibody, #ab129063, Abcam), was applied. After 
overnight incubation at 4°C, slides were washed in PBS and 
treated for 30 min with secondary antibody (ImmPRESS 
Universal reagent Mouse Anti-Rabbit Ig, Vector Labora-
tories, Burlingame, CA, USA). Then, slides were washed 
in PBS and developed in 3,3’-diaminobenzidine (Liquid 
DAB + Substrate Chromogen System, Dako). Sections 
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were counterstained in Mayer’s hematoxylin and washed in 
PBS. Slides were dehydrated in ethanol, cleared in xylene, 
embedded in DPX (Sigma Aldrich, St. Louis, MO, USA) 
and coverslipped. All sections were stained in duplicates. 
Negative controls (without primary antiserum) were run in 
parallel with antibody-incubated sections.
Evaluation of immunohistochemical reactions. All prepa-
rations were examined using Olympus BX-41 microscope 
and archived with Olympus XC50 digital camera using the 
Cell* software (Olympus, Tokyo, Japan). Hematoxylin and 
eosin (H & E) staining was performed to confirm normal 
morphology of the kidney. PLAGL1 immunostaining in-
tensity was scored in the renal corpuscles, epithelia of the 
proximal tubules, thick ascending limbs of Henle’s loop, 
distal tubules and collecting ducts. 
It was arbitrarily assumed that a very strong staining in 
distal tubules and collecting ducts reported in the kidney of 
patient No. 31 was scored for 100% and the other sections 
were scored in relation to the intensity of that staining. Sec-
tions stained by the immunohistochemical (IHC) method 
were classified (and scored) as: negative (score 0), trace 
(1–10%; score 10), weak (11–30%; score 30), moderate 
(31–60%; score 60), strong (61–80%; score 80) and very 
strong (81–100%; score 100) immunoreactivity. 
Database sequences search for putative PLAGL1 binding 
sites. BioMart data-mining tool (BioMart; http://www.bio-
mart.org/) [14] was used to retrieve the sequences located 
2-kb upstream the transcription start site (TSS) of 1054 
transcripts belonging to 478 genes which were found to be 
associated with the kidney physiology on the basis of anno-
tations available at KEGG database (Kyoto Encyclopedia 
of Genes and Genomes; http://www.genome.jp/kegg) [15] 
and The Human Proteome database (Human Protein Atlas; 
http://www.proteinatlas.org/humanproteome/kidney) [16]. 
The sequences were sought for an alignment (only exact 
matches) with the most conservative core of PLAGL1 
consensus nucleotide sequence: GGGGCCCC [1]. 
ConsensusPathDB-human (CPDB; http://cpdb.molgen.
mpg.de/) [17] was used to identify the association of 
putative PLAGL1 target genes with kidney-related path - 
way-based sets. Hypergeometric distribution-based 
over-representation analysis was performed using a list 
of queried genes as a background. Matches with FDR 
corrected p-values < 0.05 were considered as significantly 
over-represented.
Statistical analysis. Statistical analyses were performed 
using Prism 6.04 software (GraphPad software Inc., La Jolla, 
CA, USA). Normal distribution was confirmed by D’Agosti-
no & Pearson omnibus test. One-Way ANOVA followed by 
Tukey’s multiple comparisons test was used to statistically 
assess differences of PLAGL1 immunostaining intensity. 
P-values < 0.05 were considered as statistically significant. 
Pearson correlation, Mann-Whitney and Kruskal-Wallis 
tests were used to analyze the correlations between experi-
mental results and clinicopathological data of the patients.
Results
PLAGL1 immunoblotting
All tested kidney homogenates (N = 6) were positi-
ve for PLAGL1 protein exhibiting a strong band of 
PLAGL1-predicted size (approximately 51 kDa; 
Figure 1). Additional bands were present in sam-
ples used as a positive control, human tonsil, while 
in kidney homogenates additional bands were only 
barely visible.
PLAGL1 immunohistochemistry
The H & E staining confirmed a normal morphology 
of cortex and medulla in the examined parts of human 
kidneys (Figure 2A). PLAGL1 expression in kidney 
was examined by IHC staining. PLAGL1 immunore-
activity was found in the cortex and medulla of 38/39 
(97.4%) of the tested kidneys (Figure 2B). PLAGL1 
expression was noted in the epithelial cells of the pari-
etal layer of Bowman’s capsule, podocytes, mesangial 
cells and the epithelia lining proximal tubules, thick 
ascending limbs of Henle’s loop, distal tubules, and 
collecting ducts (Figures 3 and 4). Only a weak immu-
noreactivity was found in some but not all nuclei of 
thin limbs of Henle’s loop cells while no reaction was 
Figure 1. Representative Western blot showing PLAGL1 
expression in human kidney homogenate (lane B). Lane A 
— positive control — human tonsil; lane C — molecular mass 
marker Spectra Multicolor High Range Protein Ladder, 
Thermo Fisher Scientific #26625 (Waltham, MA, USA)
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noted in endothelial cells of blood vessels (Figure 4). 
PLAGL1 immunoreactivity was localized mainly in 
the cytoplasm but it was also present in the cell nuclei, 
although nuclear expression of PLAGL1 was less 
ubiquitous and weaker than the cytoplasmic. Strong 
PLAGL1 staining intensity levels were reported in the 
epithelial cells of distal tubules and collecting ducts 
(scored for 45.4 ± 3.9% and 48.7 ± 1.8%, mean ± SD, 
respectively; Figure 5). They were significantly high-
er than moderate or weak PLAGL1 expression noted 
in proximal tubules and renal corpuscles (21.8 ± 
3.1% and 13.6 ± 2.3%, respectively; Figure 5). 
PLAGL1 immunoreactivity level in thick ascending 
limbs of Henle’s loop was similar to those revealed 
in distal tubules and collecting ducts and was not 
included into statistical analysis. No correlations 
Figure 2. Structure of the normal human kidney revealed by (A) H & E staining and (B) PLAGL1 immunoreactivity.  
A. Normal histology of kidney cortex and medulla; B. Strong PLAGL1 immunoreactivity is evident in thick ascending limbs 
(TAL) of Henle’s loop in the outer stripe of the outer medulla, distal tubules (DT) in the kidney cortex and collecting 
ducts (CD) both in the cortex and medulla. Moderately intense PLAGL1 immunoreactivity is visible in proximal tubules 
and within the renal corpuscles. Immunohistochemical (IHC) staining was performed as described in Methods. Total 
magnification × 40; scale bar, 500 μm
Figure 3. PLAGL1 distribution in the cortex (A) and outer stripe of outer medulla (B) in normal human kidney. A. Strong 
PLAGL1 immunoreactivity was noted in distal tubules (DT) and macula densa (MD). Less intense PLAGL1 immunostai-
ning was present in proximal tubules (PT), podocytes (arrow) and parietal epithelium of Bowman’s capsule; B. Moderate 
PLAGL1 immunoreactivity in proximal tubules (PT) and strong immunostaining in thick ascending limbs of Henle’s loop 
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were disclosed between the PLAGL1 immunoreac-
tivity levels and clinicopathological data of patients 
(data not shown). 
Putative PLAGL1-regulated genes and their  
functional annotations
A database of TSS-upstream sequences of 478 genes 
related with kidney physiology was sought for the 
presence of PLAGL-1 binding motifs. Putative cis-re-
gulatory elements were identified in the 2-kb-upstre-
am regions of 67 transcripts of 43 genes belonging to 
different functional groups including, transmembrane 
transport, metabolic processes, intracellular signaling 
and kidney development. Nineteen genes overlap-
ped with at least one of KEGG’s kidney-related 
pathways. A list of putative PLAGL1 target genes 
with selected GO and KEGG annotations is shown 
in Table 1. Analysis of functional annotations in the 
set of putative PLAGL1 target genes identified three 
significantly (corrected p < 0.05) over-represented 
gene sets: inositol phosphate metabolic processes 
(GO), endocrine and other factor-regulated calcium 
reabsorption (KEGG) and calcium signaling pathways 
(KEGG) (Table 2).
Discussion
Earlier studies reported the presence of PLAGL1 in 
human kidney at the mRNA and protein levels by 
Northern [1] and Western blotting [18] techniques, 
respectively. However, the exact tissue-specific loca-
lization of PLAGL1 protein in human kidney was not 
determined to date. To the best of our knowledge, 
our study is the first report describing the expression 
of PLAGL1 in the structures of cortex and medulla 
of normal human kidney. We demonstrated that 
PLAGL1 staining intensity differed depending on 
the tubule type with the highest levels of PLAGL1 
protein expression in the thick ascending limbs of 
Henle’s loop, distal tubules and collecting ducts as 
opposed to renal corpuscles and proximal tubules, in 
which the immunoreactivity was weak or moderate. 
Figure 4. PLAGL1 distribution in the inner medulla of normal human kidney in longitudinal (A) and cross (B) sections. 
A. Strong immunoreactivity was noted in the cytoplasm and nuclei of collecting duct (CD) and thick ascending limbs of 
Henle’s loop (TAL); B. Weak immunoreactivity was found in some but not all nuclei of thin limbs of Henle’s loop cells 
(HL). No reaction was found in blood vessels’ (arrows) endothelial cells. IHC staining was performed as described in 
Methods. Total magnification × 200; scale bar, 100 μm
Figure 5. Semi-quantitative assessment of the intensity of 
PLAGL1 immunoreactivity in different kidney compart-
ments. RC — renal corpuscles; PT — proximal tubules;  
DT — distal tubules; CD — collecting ducts. **, *** statisti-
cally significant differences in staining intensity noted be-
tween indicated segments of uriniferous tubule, p < 0.01 and 
p < 0.001, respectively; NS — not significant (p > 0.05)
A B
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Table 1. Genes containing the core of putative PLAGL1-binding motif GGGGCCCC in their 2-kb-upstream sequence 
and overlapping kidney-related pathways (KEGG) and gene ontology
HGNC symbol Gene name Gene ontology KEGG
AGMAT Agmatine ureohydrolase (agmatinase) D G H Q
ASS1 Argininosuccinate synthase 1 D F G H I J Q R S
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide A B D E P Q 1 2 4
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 A B E 2
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 A B D E F J L P Q R S 5
BHMT2 Betaine-homocysteine S-methyltransferase 2 D G H I O Q
COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen) N
DNM1 Dynamin 1 E 2
DPEP1 Dipeptidase 1 (renal) D F G H I O Q S
DUSP15 Dual specificity phosphatase 15 P R
DYNC1LI1 Dynein, cytoplasmic 1, light intermediate chain 1 E 3
FGF9 Fibroblast growth factor 9 E F J P R S
FOXI2 Forkhead box I2 
FXYD2 FXYD domain containing ion transport regulator 2 A B E 1 2 4
GALNT9 Polypeptide N-acetylgalactosaminyltransferase 9 
GLS Glutaminase A D E G H Q 4
GNAQ Guanine nucleotide binding protein (G protein), q polypeptide D E P Q 2
HRSP12 Heat-responsive protein 12 
INSRR Insulin receptor-related receptor P
KL Klotho F J P R S 2
MFSD4 Major facilitator superfamily domain containing 4 B E
PDPK1 3-phosphoinositide dependent protein kinase 1 A E F J P R S 1
PIPOX Pipecolic acid oxidase D G H I O P Q
PLCB2 Phospholipase C, beta 2 C D M P 2
PLCB3 Phospholipase C, beta 3 (phosphatidylinositol-specific) C D M P 2
PLCB4 Phospholipase C, beta 4 C D M P 2
PNPLA1 Patatin-like phospholipase domain containing 1 
PODXL Podocalyxin-like N
PTH1R Parathyroid hormone 1 receptor C D M P 2
RAB11FIP3 RAB11 family interacting protein 3 (class II) E
RAB5C RAB5C, member RAS oncogene family D E P Q 3
RDH8 Retinol dehydrogenase 8 (all-trans) D M
RENBP Renin binding protein D G
RNF152 Ring finger protein 152 
SGK2 Serum/glucocorticoid regulated kinase 2 A B E P
SLC12A3 Solute carrier family 12 (sodium/chloride transporter), member 3 A B E
SLC13A1 Solute carrier family 13 (sodium/sulfate symporter), member 1 A B E K
SLC22A8 Solute carrier family 22 (organic anion transporter), member 8 A B E F J K S
SLC25A10 Solute carrier family 25 (mitochondrial carrier; dicarboxylate transporter), 
member 10 
A B D E G H O Q 4
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 A B D E G 6
SLC2A9 Solute carrier family 2 (facilitated glucose transporter), member 9 A B D E G L Q
SLC8A1 Solute carrier family 8 (sodium/calcium exchanger), member 1 A B E F J R S 2
SLC9A3* Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 A B E L 4
GO biological processes: A — ion transport GO:0006811; B — transmembrane transport GO:0055085; C — inositol phosphate metabolic process 
GO:0043647; D — small molecule metabolic process GO:0044281; E — transport GO:0006810; F — response to nitrogen compound GO:1901698; 
G — organic acid metabolic process GO:0006082; H — cellular amino acid metabolic process GO:0006520; I — cellular modified amino acid meta-
bolic process GO:0006575; J — response to organonitrogen compound GO:0010243; K — sulfur compound transport GO:0072348; L — hydrogen 
transport GO:0006818; M — organic hydroxy compound metabolic process GO:1901615; N — glomerulus development GO:0032835; O — sulfur 
compound metabolic process GO:0006790; P — phosphorus metabolic process GO:0006793; Q — organonitrogen compound metabolic process 
GO:1901564; R — cellular response to endogenous stimulus GO:0071495; S — response to oxygen-containing compound GO:1901700  
KEGG pathways: 1 — aldosterone-regulated sodium reabsorption hsa04960; 2 — endocrine and other factor-regulated calcium reabsorption 
hsa04961; 3 — vasopressin-regulated water reabsorption hsa04962; 4 — proximal tubule bicarbonate reclamation hsa04964; 5 — collecting duct 
acid secretion hsa04966; 6 — renal cell carcinoma hsa05211
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For each patient included in this study the lack of 
lesions in the analyzed kidney section was confirmed 
by H & E staining. The normal morphology of kidney 
tissue can be also supported by the fact that the levels 
of PLAGL1 immunoreactivity did not correlate with 
clinicopathological data of patients (data not shown). 
Additionally, by the Western blotting technique we 
confirmed that the antibodies used in our IHC study 
specifically bind to a 51 kDa-protein in homogenates 
obtained from normal human kidney. The molecular 
mass of detected band corresponds well to the one of 
PLAGL1 isoform 2 (50.8 kDa). Our morphological 
and biochemical data are in concordance with bioche-
mical study which showed strong level of PLAGL1 
protein expression in the homogenates of human 
kidney papilla and medulla with weak expression in 
the kidney cortex [18]. 
It has been established that the epithelial cells of 
any given segment of the uriniferous tubule [divided 
according to the current morphological nomenclatu-
re into the proximal tubule, the intermediate (thin) 
tubule, the distal tubule and the collecting duct] are 
homogeneous and distinct for that segment, and 
that structural differences between them reflect the 
localization and function of transport proteins and 
receptors [19]. The different immunoreactivity of 
the PLAGL1 protein in the various parts of nephron 
and collecting tubules demonstrated in our study 
may express its involvement in specific transepithelial 
transport processes. However, due to the multiplicity 
of the luminal and basolateral transport proteins we 
can implicate only some of them in the context of 
PLAGL1 distribution in normal human kidney. The-
refore we hypothesize that differences in PLAGL1 
immunostaining could reflect the involvement of 
PLAGL1 in the process of nuclear receptor-regula-
ted expression of proteins such as Na+/K+-ATPase 
subunits. PLAGL1 mRNA expression was found 
in the human kidney and others tissues which are 
regulated by steroid hormones as compared to non
-steroid dependent other organs and tissues [1]. It 
was documented that PLAGL1 protein may directly 
and indirectly co-activate the nuclear receptors [12]. 
Furthermore, the Human Protein Atlas documen-
tation of human kidney immunostained against the 
mineralocorticoid receptor (NR3C2) protein showed 
a similar pattern of staining distribution as PLAGL1 
found in our study, i.e. the cytoplasmic staining of 
epithelial cells was visible in all nephron tubules with 
a stronger immunoreactivity in the distal tubules 
(Human Protein Atlas, http://www.proteinatlas.org/ 
/ENSG00000151623-NR3C2/tissue/kidney) [20]. Such 
mechanisms of PLAGL1 action strongly suggest its 
potential role in kidney as a factor contributing to the 
renal aldosterone-regulated processes. 
Other studies also report that PLAGL1 may affect 
kidney water homeostasis. The water-restricted mice, 
i.e. subjected to hyperosmotic condition, had incre-
ased levels of PLAGL1 mRNA as well as PLAGL1 
protein in the kidney papilla (assessed by Western 
blotting) as opposed to lower expression of both 
mRNA and protein in the kidney cortex. Similarly, 
much lower PLAGL1 protein levels were found in 
normal human kidney in cortex than in medulla and 
papilla [18]. The demonstration that PLAGL1 is 
up-regulated under hypertonic stress and negatively 
regulates expression of the sorbitol dehydrogenase 
suggests that this protein may be involved in the or-
ganic osmolyte regulation in mammalian kidney [18].
Considering the alternative roles of PLAGL1 in 
kidney, we assumed that its transcriptional activity can 
be mediated in two ways: directly by DNA-binding 
and indirectly by modulating the activity of other 
transcription factors. Since PLAGL1 can directly 
Table 2. Over-represented gene ontology annotation sets (GO) and pathways (KEGG) of the genes containing putative 
PLAGL1-binding motif(s) GGGGCCCC in their 2-kb-upstream sequence
Over-represented gene-sets Source Overlapping genes Count Fold p-value Corrected 
p-value
Inositol phosphate metabolic 
process
BP level 3 
GO:0043647
PTH1R; PLCB2; PLCB3; PLCB4 4 8.78 0.0003 0.0434
Endocrine and other factor-
-regulated calcium reab-
sorption (Homo sapiens)
KEGG: hsa04961 PTH1R, PLCB2, PLCB3, PLCB4, 
GNAQ, ATP1B2, KL, ATP2B1, 
DNM1, SLC8A1, FXYD2
11 2.60 0.0011 0.0200
Calcium signaling pathway  
— Homo sapiens (human)
KEGG: hsa04020 PLCB2; PLCB3; PLCB4; GNAQ; 
ATP2B1; SLC8A1
6 2.98 0.0094 0.0332
Count — number of members of predefined gene-set (GO or KEGG) in user-specified gene set; Fold — ratio between observed (en-
riched) and expected (background corrected) incidence of members of predefined gene-set (GO or KEGG) in user-specified gene set; 
p-values and corrected p-values — are calculated according to the hypergeometric test and then corrected for multiple testing using the 
false discovery rate method as described in http://cpdb.molgen.mpg.de/ [17]
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regulate gene transcription by sequence-specific 
DNA binding in the promoter region of target genes 
[1, 8] we sought for putative PLAGL1-regulated 
genes among the group of genes associated with 
kidney physiology. By in sillico screening of promoter 
sequences for alignment with the core of PLAGL1 
DNA-binding site GGGGCCCC we designated 
43 candidate genes for PLAGL1-regulated genes. The 
set of putative PLAGL1-target genes was analyzed for 
functional annotations revealing gene ontology and 
associations with kidney-related pathways (Table 1). 
The PLAGL1-target genes were found to be associated 
mainly with transport, including SLC- and ATPase- 
-mediated membrane transport, phosphate metabo-
lism including Gq/PLC-beta signaling pathway and 
glomerulus filtration barrier components (Table 2). 
Bioinformatics analysis revealed that putative 
PLAGL1-binding motifs are over-represented in 
the set of genes involved in the regulated calcium 
reabsorption and calcium signaling (Tables 1 and 2). 
Hypothetical PLAGL1 targets included also genes 
coding for membrane transporters and ATPases, 
members of the inositol phosphate pathway, klotho 
glucuronidase, dynamin and parathyroid receptor 1 
(Table 1). Since PLAGL1 can act as a transcriptional 
cofactor of various nuclear receptors [12], the interac-
tion of PLAGL1 with vitamin D, estrogen or androgen 
receptors cannot be excluded. Consequently, we hy-
pothesize that PLAGL1 could be a factor which can 
both directly, by DNA-binding and transactivation, 
or indirectly, regulate or modulate the transcriptio-
nal activity of mineralocorticoid and glucocorticoid 
receptors [12]. The hypothetical involvement of 
PLAGL1 in the control of both calcium reabsorption 
and aldosterone-regulated sodium-potassium trans-
port can be supported by the fact that segments of 
the uriniferous tubule known as localization for these 
processes [21, 22] overlap with the pattern of PLAGL1 
expression observed in the present study. It was also 
documented that aldosterone-activated mineralo-
corticoid receptors can influence the expression of 
sodium bicarbonate transporters SLC9A3 and Na+/ 
/K+-ATPase subunit alpha in the epithelial cells of 
proximal tubule [23]. PLAGL1-binding sequences 
were found in the promoter of SLC2A1 gene encoding 
for GLUT1 transporter which is present in the baso-
lateral membrane of the proximal tubule epithelial 
cells [24]. The expression of SLC2A1 is regulated 
by the VHL/HIF1 pathway and associated with the 
progression of renal cell carcinoma [25], indicating 
another hypothetical role of PLAGL1 transcriptional 
activity under pathological conditions. The presence 
of PLAGL1 protein in the renal corpuscles could be 
also associated with the regulation of the expression 
PODXL and COL4A3 genes which protein products, 
podocalyxin and collagen type IV, play a key role in 
the maintaining and functioning of the renal filtration 
barrier [26, 27]. Taken together, these findings could 
explain the ubiquitous renal immunoreactivity of the 
PLAGL1 protein observed in the present study.
In conclusion, we report experimental data docu-
menting a widespread but quantitatively differentiated 
immunoexpression of the PLAGL1 protein in normal 
human kidney. We hypothesize that PLAGL1 can 
regulate expression of numerous genes by acting as 
a transcription factor and/or transcriptional coactivator/ 
/corepressor of nuclear receptors. These two modes 
of PLAGL1 action can overlap, showing a potency 
of PLAGL1 to integrate and synergize several regu-
latory pathways by the way of its DNA-binding and 
protein-binding activities. The exact role of PLAGL1 
in the physiology (and pathology) of kidney cannot 
be elucidated without further studies. 
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